Related Experiment Video
Updated: Apr 28, 2026
07:05
Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea
Published on: November 9, 2016
24.5K
Botulinum Toxin Type A Injections in the Bladder Wall-An Effective Treatment for Urinary Incontinence with Low
Francisco Cruz1,2,3, Martin C Michel4,5, Yasuhiko Igawa6
1Department of Urology, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal.
Toxins
|April 27, 2026
Summary
Botulinum toxin type A injections improve urinary incontinence but require repeated procedures. New methods are being explored to enhance treatment adherence and reduce patient discomfort and side effects.
Area of Science:
- Urology
- Pharmacology
- Biotechnology
Background:
- Botulinum toxin type A (BoNT/A) injections are a key treatment for refractory urinary incontinence in neurogenic detrusor overactivity (NDOi) and overactive bladder syndrome (OABi).
- Patient adherence to repeated intravesical BoNT/A injections is low due to pain, discomfort from cystoscopies, urinary tract infections (UTIs), and transient urinary retention.
Purpose of the Study:
- To review current challenges with BoNT/A bladder injections for urinary incontinence.
- To explore novel strategies for improving BoNT/A delivery and patient adherence.
Main Methods:
- Review of existing literature on BoNT/A for urinary incontinence.
- Discussion of alternative delivery methods including transabdominal injection, Electromotive Drug Administration (EMDA), Extracorporeal Shock Wave Lithotripsy (ESWL)-assisted instillation, and nano-formulations.
Main Results:
- Current BoNT/A injection protocols face significant adherence issues.
- Investigational methods like EMDA show promise but lack reproducibility.
- ESWL-assisted instillation and nano-formulations are preliminary with limited data.
Conclusions:
- Improving patient adherence and reducing adverse events are critical for long-term BoNT/A efficacy in urinary incontinence.
- Further research into innovative, non-invasive, or less invasive delivery systems is essential to overcome current treatment limitations.
Related Concept Videos
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
2.2K
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
2.2K
01:31Skeletal Muscle Relaxants: Therapeutic Uses
1.2K
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
1.2K
01:23Urinary Bladder
4.6K
The urinary bladder is a hollow, muscular sac that temporarily stores urine before it is expelled from the body. It can hold approximately 600 mL of urine prior to micturition. The bladder is retroperitoneal and located behind the pubic symphysis in the pelvic floor.
In males, the bladder is situated in front of the rectum, while in females, it is positioned anterior to the vagina and uterus. The bladder floor contains an inverted triangular area called the trigone, defined by the two ureteric...
In males, the bladder is situated in front of the rectum, while in females, it is positioned anterior to the vagina and uterus. The bladder floor contains an inverted triangular area called the trigone, defined by the two ureteric...
4.6K
01:19Anatomy of the Genitourinary System II: Bladder and Urethra
3.6K
The lower urinary system consists of the urinary bladder and urethra, which are essential in storing and expelling urine from the body. Together with the internal and external sphincters, these structures work together to regulate urination effectively.Anatomy of the BladderThe urinary bladder is a muscular, stretchable organ behind the pubic bone and in front of the rectum. In females, the bladder is positioned anterior to the vagina and inferior to the uterus, while in males, it is located...
3.6K
01:27Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
1.3K
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
1.3K
01:17Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
3.5K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
3.5K